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Background: Late cardiovascular events have been reported after percutaneous revascularization procedures; therefore, long-term follow up has 
been emphasized. A high risk group are patients (pts) being treated for in-stent restenosis (ISR). We examined the 5-year follow up of the SISR study 
(Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis).
Methods: The SISR trial enrolled 384 pts with ISR of bare metal stents. 259 pere treated with a Sirolimus-eluting stent (SES) and 125 with 
vascular brachytherapy (VBT). The primary endpoint was 9 mo target vessel failure (TVF) (a composite of cardiac death, myocardial infarction, or 
target vessel revascularization). Pts were followed at 30 days, 6 and 9 months (mo), and then 1-5 years. This report deals with the final 5-year 
clinical outcome data of TVF, target lesion revascularization (TLR), and adjudicated probable/definite stent thrombosis (ST).
Results: There were no differences in overall death/cardiac death at 5 years (8.3%-SES vs 6.4%-VBT). 9 mo TVF as well as 36 month data has been 
previously published. 5 year follow up was: 
Endpoints† VBT SES Difference 95% CI P-value‡
TVF
9 mo 21.9% 12.5% 9.4% (8.8%, 10.0%) 0.017
36 mo 32.1% 24.7% 7.4% (6.5%, 8.3%) 0.085
60 mo 38.7% 35.6% 3.1% (2.0%, 4.2%) 0.349
Definite/probable ST
9 mo 0.8% 0.8% 0.0% (-0.5%, 0.5%) 0.975
36 mo 2.5% 3.6% -1.1% (-1.4%, -0.8%) 0.573
60 mo 2.5% 5.9% -3.4% (-3.8%, -3.0%) 0.182
Any very late ST 1.7% 4.3% -2.6% (-2.9%, -2.3%) 0.2326
TLR
9 mo 19.5% 9.0% 10.5% (9.9%, 11.1%) 0.0028
36 mo 28.0% 18.4% 9.6% (8.8%, 10.4%) 0.0189
60 mo 32.7% 26.5% 6.2% (5.2%, 7.2%) 0.1002
† Estimates calculated with Kaplan-Meier Methods; standard error estimates by Peto formula
‡Log-Rank P-values
Conclusions: Pts with ISR of BMS are at increased risk for subsequent events. Even in this high risk group at 5 years after treatment with SES, very 
late ST occurs in less than 5% of pts. TVR rates increase between 36 and 60 months but are still < 30%.
